Get notified when LGND files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: LGND LIGAND PHARMACEUTICALS INC 8-K

Ligand closes $700M convertible notes offering, deploys $60M for share buyback

Filed June 25, 2026 · Period ending June 25, 2026 · ~1 min read

Key Changes

  • high

    Completed $700M zero-coupon convertible notes due 2031, convertible at $334.27/share (27.5% premium to pricing-date close). Net proceeds $678.2M after fees.

    Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
  • high

    Used $60M of proceeds to repurchase 228,859 shares at $262.17 in privately negotiated transactions concurrent with pricing, offsetting potential dilution.

    Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
  • high

    Entered note hedge transactions (strike $334.27) and sold warrants (strike $524.34) covering ~2.09M shares. Hedges reduce conversion dilution; warrants dilutive above $524.34.

    Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FRVO 10-Q) is open in full — no account needed.

Partner

Trade LGND commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 26, 2026 12:11 AM